Interviews

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses the current and emerging roles of PARP inhibition in ovarian cancer.

Thomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the issues that still need to be addressed in diffuse large B-cell lymphoma.

Deepak A. Kapoor, MD, Chairman and CEO of Integrated Medical Professionals, discusses how physicians can adapt to the new value-based payment models.

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future of thyroid cancer treatment.

Navesh K. Sharma, DO, PhD, associate professor of Radiology, Division of Radiology and Oncology, Penn State Hershey Medical Center, section chief of Radiation Oncology, Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study in patients with metastatic colorectal cancer (mCRC).

David A. Reardon, MD, clinical director, center for neuro-oncology, Dana-Farber Cancer Institute, discusses the inadequacy of the current standard of care in glioblastoma (GBM).

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, speaks on distinguishing between the different subtypes of sarcomas.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discussed the best treatment option for a patient with metasatic castration-resistant prostate cancer (mCRPC) during the LUGPA Annual Meeting.

Jeffrey Schneider, MD, chief of hematology and medical oncology, Winthrop University Hospital, discusses the benefits of Myriad's myPlan in determining high-risk patients with non-small cell lung cancer (NSCLC).

Debu Tripathy, MD, chair, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the potential for immunotherapy in the treatment of HER2+ breast cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the future of biomarkers in prostate cancer.

Howard S. Hochster, MD, professor of Medical Oncology, and Yale Cancer Center Associate Director (for Clinical Sciences), discusses steps that can be taken to tackle some of the challenges that remain in the field of pancreatic cancer.

Steven Coutre, MD, professor of medicine, Stanford University School of Medicine, discusses the benefits and drawbacks of the different frontline treatment options for chronic lymphocytic leukemia (CLL).

Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussy in Paris, discusses overall survival (OS) results of a recent study evaluating dabrafenib and trametinib in melanoma.

Toni Choueiri, MD, discusses some of the ongoing clinical trials in metastatic renal cell carcinoma (mRCC).

Lidija Kandolf-Sekulovic, MD, PhD, associate professor of Dermatology at the Military Medical Academy in Belgrade, Serbia, discusses a recent survey that examined the lack of access to lifesaving drugs in European melanoma patients.

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses his vision for breast cancer treatment in the next 5 to 10 years.

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses how mutation status effects individualization of treatment in metastatic colorectal cancer (mCRC).

Toni Choueiri, MD, discusses the results of the ALLIANCE A031203 trial comparing cabozantinib and sunitinib in metastatic renal cell carcinoma (mRCC).

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discuses exciting advancements in the field of sarcoma.

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the future role of PD-L1 testing in lung cancer.

George Somlo, MD, medical oncologist, City of Hope, discusses recent advancements in multiple myeloma treatment.

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the results of a recent first-line study of pembrolizumab in advanced urothelial cancer.

Rahul Tendulkar, MD, associate, Cleveland Clinic, discusses findings of a recent study looking at post-prostatectomy radiation and its impact on prostate cancer mortality.

Heather Wakelee, MD, associate professor of medicine at Stanford University Medical Center, discusses a recent trial looking at atezolizumab for NSCLC treatment.

Meena Savur Moran, MD, radiation oncologist, professor, Therapeutic Radiology, director, Breast Cancer Radiotherapy Program, Yale Cancer Center, discusses considerations oncologists take when treating patients with breast cancer of different ethnic backgrounds.

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the future of HER2+ breast cancer treatment.

Benjamin P. Levy, MD, discusses how Myriad's myPlan addresses the risk of recurrence in lung cancer.